BioSpace News Archive

Aidoc, the leading provider of healthcare AI solutions, announced today that it received its 9th FDA 510(k) clearance for triage and notification of brain aneurysm.

ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announces the results from the NOPHO sponsored Phase 2 trial of eryaspase in ALL patients are now published in the British Journal of Haematology.

Mersana Therapeutics, Inc. announced that on April 1, 2022, an authorized sub-committee of the Compensation Committee of the Board of Directors of Mersana granted inducement awards consisting of stock options to purchase an aggregate of 51,150 shares of its common stock to four new employees whose employment commenced in March 2022.

Talaris Therapeutics, Inc. (Nasdaq: TALS), today shared new data on COVID-19 outcomes among living donor kidney transplant (LDKT) patients treated in the Company’s Phase 2 trial of investigational cell therapy product FCR001 (NCT00497926).

Microbot Medical Inc., seeking to continuously enhance its core capabilities, announced the promotion of Rachel Vaknin as its Chief Financial Officer.

Cytokinetics, Incorporated announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on Wednesday, April 13, 2022 at 11:00 AM ET.

Adverum Biotechnologies, Inc. announced that it has received feedback via a Type C meeting written response from the U.S. Food and Drug Administration related to Adverum’s planned Phase 2 trial of ADVM-022 in wet age-related macular degeneration.

HTG Molecular Diagnostics, Inc. announced that it has improved the sample preparation protocol for its miRNA Whole Transcriptome Assay so that it is now harmonized with the HTG Transcriptome Panel.

ENSEM Therapeutics Inc., a Boston-based biotechnology company focusing on high value and difficult-to-drug oncology targets, announced the closing of a series A2 financing.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation as part of the 21st Annual Needham Virtual Healthcare Conference.